Process Industries
Mitsubishi Chemical Holdings Corp.
In the news
- Coronavirus puts sumo tournament at risk as Japan hunkers down Feb 27, 2020
- Japan earnings outlook worsens as slump sucks in services Feb 11, 2020
- Capitalism's flaws spur soul-searching, from Bill Gates to AI Jan 13, 2020
- US resilience brightens spirits in corporate Japan Dec 26, 2019
- Singapore fund raises $106 million to tackle plastic pollution Dec 4, 2019 See more articles on Mitsubishi Chemical Holdings Corp.
Business Summary
Mitsubishi Chemical Holdings Corp. engages in the management of its group companies. It operates through the following segments: Electronic Applications, Designed Materials, Health Care, Chemicals, Polymers and Others. The Electronic Applications segment covers recording media and electronic-related products. The Designed Materials segment offers polyester films, food ingredients, films, fine chemicals, polymer processing products, composite materials, inorganic chemicals, water treatment systems, and chemical fibers. The Health Care segment manufactures and sells pharmaceuticals, diagnostic reagents, and clinical testing products. The Chemicals segment deals with basic chemical and carbon products. The Polymers segment produces synthetic resins. The Others segment includes engineering, transportation, and warehousing services. The company was founded on October 3, 2005 and is headquartered in Tokyo, Japan.
Financial Highlights
| Mar 2019 | JPY | USD |
| Revenue | 3,923.44B | 35,379.91M |
| Gross Profit | 1,101.55B | 9,933.34M |
| Operating income | 300,861M | 2,713.03M |
| Income before tax | 288,056M | 2,597.56M |
| Net income | 169,530M | 1,528.74M |
| EBITDA | 500,193M | 4,510.52M |
| Diluted EPS | 110.04 | 0.99 |
| Dividends Per Share | 40 | 0.36 |
| Total Assets | 5,572.50B | 50,345.65M |
| Total liabilities | 3,546.65B | 32,042.77M |
| Total equity | 1,377.94B | 12,449.26M |
| Operating cash flow | 415,575M | 3,747.47M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 3,656.27B | 3,543.35B | 3,376.05B | 3,724.40B | 3,923.44B |
| Gross Profit | 830,081M | 1,015.04B | 1,009.39B | 1,120.06B | 1,101.55B |
| Operating income | 165,681M | 295,965M | 287,903M | 355,745M | 300,861M |
| Income before tax | 165,621M | 238,808M | 241,379M | 344,077M | 288,056M |
| Net income | 60,859M | 125,227M | 153,673M | 211,788M | 169,530M |
| EBITDA | 338,078M | 478,621M | 461,943M | 534,640M | 500,193M |
| Diluted EPS | 41.38 | 35.03 | 105.95 | 136.05 | 110.04 |
| Dividends Per Share | 13 | 15 | 20 | 32 | 40 |
| Total Assets | 4,323.03B | 4,223.77B | 4,463.54B | 4,701.41B | 5,572.50B |
| Total liabilities | 2,734.43B | 2,627.62B | 2,765.35B | 2,781.92B | 3,546.65B |
| Total equity | 981,464M | 972,197M | 1,091.39B | 1,285.75B | 1,377.94B |
| Operating cash flow | 329,776M | 299,612M | 396,643M | 397,940M | 415,575M |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
| Revenue | 33,282.31M | 29,507.20M | 31,176.79M | 33,603.94M | 35,379.91M |
| Gross Profit | 7,556.04M | 8,452.80M | 9,321.47M | 10,105.90M | 9,933.34M |
| Operating income | 1,508.15M | 2,464.64M | 2,658.69M | 3,209.75M | 2,713.03M |
| Income before tax | 1,507.61M | 1,988.66M | 2,229.05M | 3,104.47M | 2,597.56M |
| Net income | 553.98M | 1,042.82M | 1,419.12M | 1,910.88M | 1,528.74M |
| EBITDA | 3,077.45M | 3,985.70M | 4,265.89M | 4,823.85M | 4,510.52M |
| Diluted EPS | 0.37 | 0.29 | 0.97 | 1.22 | 0.99 |
| Dividends Per Share | 0.11 | 0.12 | 0.18 | 0.28 | 0.36 |
| Total Assets | 36,047.84M | 37,579.73M | 40,056.95M | 44,206.99M | 50,345.65M |
| Total liabilities | 22,801.22M | 23,378.46M | 24,816.92M | 26,158.19M | 32,042.77M |
| Total equity | 8,183.98M | 8,649.82M | 9,794.47M | 12,089.79M | 12,449.26M |
| Operating cash flow | 3,001.88M | 2,495.01M | 3,662.86M | 3,590.46M | 3,747.47M |
Valuation Measures
| Mar 2019 | |
| PER | 6.53 |
| ROA | 3.30% |
| ROE | 12.72% |
| Operating margin | 7.66% |
| Profit margin | 4.32% |
Key executives
- President & Director: Hitoshi Ochi
- CFO & Managing Executive Officer: Hidefumi Date
- Director & Chief Compliance Officer: Ken Fujiwara
- Executive Officer, Manager-Public Relations & IR: Hajime Takasaka
- Manager-Business Administration: Motohiro Oki
Shareholders
- Mitsubishi Chemical Holdings Corp. (5.5%)
- Meiji Yasuda Life Insurance Co. (4.2%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (4.0%)
- Nomura Asset Management Co., Ltd. (3.6%)
- Asset Management One Co., Ltd. (3.6%)
- Nippon Life Insurance Co. (2.8%)
- BlackRock Fund Advisors (2.5%)
- The Vanguard Group, Inc. (2.3%)
- Mitsubishi UFJ Financial Group, Inc. (1.3%)
- Daiwa Asset Management Co. Ltd. (1.3%)
Contact Details
- Website:http://www.mitsubishichem-hd.co.jp
- Address: Palace Building, 1-1-1 Marunochi, Tokyo, 100-8251, Japan
- Phone: +81.3.6748.7200
Related Companies
- MCPP Innovation LLC
- Mitsubishi Chemical Lucite Group Ltd.
- Diamond Edge Ventures, Inc.
- Mitsubishi Chemical Holdings Board Incentive Plan
- Verbatim Corp.
- Mitsubishi Chemical Imaging Corp.
- MEP Technical Center Asia Ltd.
- MCC Group Holdings (UK) Ltd.
- Life Science Institute, Inc.
- Mitsubishi Chemical Holdings Europe GmbH
- AmperVertice Lda.
- Mitsubishi Plastics Agricultural Film Technology Wuxi Co. Ltd.
- Ryoukou Industrial Co. Ltd.
- Mitsubishi Chemical Analysis Co. Ltd.
- Rhombic Corp. (Japan)
- Verbatim Southern Africa
- Mitsubishi Chemical Holdings (Beijing) Co. Ltd.
- Tai Young High Tech Co. Ltd.
- MCC PTA Asia Pacific Pte Ltd.
- Mitsubishi Chemical Holdings America, Inc.
- Advanced Plastics Compounds Singapore Pte Ltd.
- PT Mitsubishi Chemical Indonesia
- Yoshitomi Engineering Ltd.
- Mitsubishi Chemical Hldgs Business Association
- Kaiteki Institute, Inc.
- Mitsubishi Chemical Infonics Pte Ltd.
- Nihon Gosei Sangyo KK
- Ryoju Corp.
- Mitsubishi Chemical Agri, Inc.
- Japan Unipet Co. Ltd.
Competitors
- Evonik Industries AG
- Sumitomo Chemical Co., Ltd.
- DuPont de Nemours, Inc.
- Eastman Chemical Company
- LG Chem Ltd.
- Arkema SA
- Kolon Industries, Inc.
- Kolon Life Science Inc.
- Sinochem International Corporation Class A
- Celanese Corporation
- Polyplex (Thailand) Public Co. Ltd.
- Covestro AG
- UFlex Limited
- Adamas Pharmaceuticals, Inc.
- Acorda Therapeutics, Inc.
- Linde plc
- Fuwei Films (Holdings) Co., Ltd.
- Cytokinetics, Incorporated
- Shenzhen Capchem Technology Co., Ltd. Class A
- Tredegar Corporation
- Voyager Therapeutics, Inc.
- Chemocentryx, Inc.
- FibroGen, Inc.
- Aquestive Therapeutics, Inc.
- Valneva SE
- BiondVax Pharmaceuticals Ltd. Sponsored ADR
- GrafTech International Ltd.
- Green Seal Holding Ltd.
- Axovant Gene Therapies Ltd.
- OCI Partners LP
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 30 Mar, 2020